The Pharmacological effects of novel 5-fluoro-N-(9,10-dihydro-9,10- dioxoanthracen-8-yl)-1H-indole-2-carboxamide derivatives on plasma lipid profile of Triton-WR-1339-induced Wistar rats

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 28, Issue 4, 2013, Pages 863-869

  Shattat, Ghassan ^a   Al Qirim, Tariq ^a   Sheikha, Ghassan Abu ^a   Al Hiari, Yusuf ^b   Sweidan, Kamal ^b   Al Qirim, Rania ^a   Hikmat, Suhair ^a   Hamadneh, Lama ^a   Al Kouz, Sameer ^a  

^a AL ZAYTOONAH UNIVERSITY OF JORDAN   (Jordan)

^b UNIVERSITY OF JORDAN   (Jordan)

Author keywords

5 fluoro N (9,10 dihydro 9,10 dioxoanthracen 8 yl) 1H indole 2 carboxamides; Hypolipidemic activity; Triton WR 1339 induced hyperlipidemic rats

Indexed keywords

5 FLUORO N (9,10 DIHYDRO 1 HYDROXY 9,10 DIOXOANTHRACEN 4 YL) 1H INDOLE 2 CARBOXAMIDE; 5 FLUORO N (9,10 DIHYDRO 9,10 DIOXOANTHRACEN 1 YL) 1H INDOLE 2 CARBOXAMIDE; 5 FLUORO N (9,10 DIHYDRO 9,10 DIOXOANTHRACEN 3 YL) 1H INDOLE 2 CARBOXAMIDE; AMIDE; ANTILIPEMIC AGENT; BEZAFIBRATE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; N (1 BROMO 9,10 DIHYDRO 3 METHYL 9,10 DIOXOANTHRACEN 4 YL) 5 FLUORO 1H INDOLE 2 CARBOXAMIDE; N (1 CHLORO 9,10 DIHYDRO 9,10 DIOXOANTHRACEN 5 YL) 5 FLUORO 1H INDOLE 2 CARBOXAMIDE; TRIACYLGLYCEROL; TYLOXAPOL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROL GROUP; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; HEART PROTECTION; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ANTHRAQUINONES; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPERLIPIDEMIAS; HYPOLIPIDEMIC AGENTS; INDOLES; LIPIDS; MALE; MOLECULAR STRUCTURE; POLYETHYLENE GLYCOLS; RATS; RATS, WISTAR;

EID: 84880080155     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.3109/14756366.2012.692085     Document Type: Article

References (30)

1. Sunil C, Ignacimuthu S, Kumarappan C. Hypolipidemic activity of Symplocos cochinchinensis S. Moore leaves in hyperlipidemic rats. J Nat Med 2012;66:32-38.
2. Yokozawa T, Ishida A, Cho EJ, Nakagawa T. The effects of Coptidis Rhizoma extract on a hypercholesterolemic animal model. Phytomedicine 2003;10:17-22.
3. Xiaoli Y, Kai H, Xiaokang Z, Baoshun Z, Xin C, Jun Y, Xuegang L. Synthesis and antihyperlipidemic efficiency of berberinebased HMG-CoA reductase inhibitor. Med Chem Res 2011, DOI: 10.1007/s00044-011-9651-z.
4. Koh KK, Quon MJ, Rosenson RS, Chung WJ, Han SH. Vascular and metabolic effects of treatment of combined hyperlipidemia: focus on statins and fibrates. Int J Cardiol 2008;124:149-159.
5. Al-Hiari Y, Shattat G, Al-Qirim T, El-Huneidi W, Sheikha GA, Hikmat S. Antihyperlipidemic properties of novel N-(benzoylphenyl)-5-substituted-1H- indole-2-carboxamides in Triton WR-1339-induced hyperlipidemic rats. Molecules 2011;16:8292-8304.
6. Hayashi H, Niinobe S, Matsumoto Y, Suga T. Effects of Triton WR-1339 on lipoprotein lipolytic activity and lipid content of rat liver lysosomes. J Biochem 1981;89:573-579.
7. Friedman M, Byers SO. Mechanism underlying hypercholesteremia induced by triton WR-1339. Am J Physiol 1957;190:439-445.
8. Bosies E, Heerdt R, Kuknle F, Schmidt H, Stach H. Hypoglycemically and hypolipidemically active derivatives of phenylalkane carboxylic acids. US Patent 150207, 1980.
9. Dasseux H, Oniciu D. Ketone compounds and compositions for cholesterol management and related uses. US Patent 325529, 2002.
10. Kopin S, Carey M, Wang D. Methods of altering intestinal motility and absorption of hydrophobic compounds through the use of agonists and/or antagonists of the cholecystokinin-1 receptor. US Patent 224869,2005.
11. Sher M, Ellsworth A. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds. US Patent 7098235,2003.
12. Shahwan M, Shattat G, Al-Qirim T, Sheikha GA, Al-Hiari Y, El-Huneidi W et al. Synthesis and pharmacological evaluation of novel substituted and unsubstituted N-(benzoylphenyl)-1Hindole-2-carboxamides as potent antihypertriglyceridemic agents. Z Naturforsch, C, J Biosci 2010;65:309-316.
13. Shattat G, Al-Qirim R, Al-Hiari Y, Sheikha GA, Al-Qirim T, El-Huneidi W et al. Synthesis and anti-hyperlipidemic evaluation of N-(benzoylphenyl)-5- fluoro-1H-indole-2-carboxamide derivatives in Triton WR-1339-induced hyperlipidemic rats. Molecules 2010;15:5840-5849.
14. Al-Qirim T, Shahwan M, Shattat G, Al-Hiari Y, Abu-Sheikha G, Zaidi S. Pharmacological evaluation of novel indole-2-carboxamides as potent lipid-lowering agents in Triton-WR-1339-induced hyperlipidemic rats. Z Naturforsch, C, J Biosci 2009;64:619-625.
15. Shattat G, Al-Qirim T, Sweidan K, Shahwan M, El-Huneidi W, Al-Hiari Y. The hypolipidemic activity of novel benzofuran-2-carboxamide derivatives in Triton WR-1339-induced hyperlipidemic rats: a comparison with bezafibrate. J Enzyme Inhib Med Chem 2010;25:751-755.
16. Nakajima T, Tanaka N, Kanbe H, Hara A, Kamijo Y, Zhang X et al. Bezafibrate at clinically relevant doses decreases serum/liver triglycerides via down-regulation of sterol regulatory element-binding protein-1c in mice: a novel peroxisome proliferator-activated receptor alpha-independent mechanism. Mol Pharmacol 2009;75:782-792.
17. Mori Y, Tokutate Y, Oana F, Matsuzawa A, Akahane S, Tajima N. Bezafibrate-induced changes over time in the expression of uncoupling protein (UCP) mRNA in the tissues: a study in spontaneously type 2 diabetic rats with visceral obesity. J Atheroscler Thromb 2004;11:224-231.
18. Litchfield JT Jr, Wilcoxon F. A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 1949;96:99-113.
19. Schurr PE, Schultz JR, Parkinson TM. Triton-induced hyperlipidemia in rats as an animal model for screening hypolipidemic drugs. Lipids 1972;7:68-74.
20. Kellner A, Correll JW, Ladd AT. The influence of intravenously administered surface-active agents on the development of experimental atherosclerosis in rabbits. J Exp Med 1951;93:385-398.
21. Ohmori K, Yamada H, Yasuda A, Yamamoto A, Matsuura N, Kiniwa M. Effects of a novel anti-hyperlipidemic agent, S-2E, on blood lipid levels in rats with fructose-induced hypertriglyceridemia. Pharmacology 2004;72:240-246.
22. Harnafi H, Bouanani Nel H, Aziz M, Serghini Caid H, Ghalim N, Amrani S. The hypolipidaemic activity of aqueous Erica multiflora flowers extract in Triton WR-1339 induced hyperlipidaemic rats: a comparison with fenofibrate. J Ethnopharmacol 2007;109:156-160.
23. Lauk L, Galati EM, Forestieri AM, Kirjavainen S, Trovato A. Mucuma pruriens infusion lowers cholesterol and total lipid plasma levels in the rats. Phytother Res 1989;3:263-264.
24. Khanna AK, Chander R, Singh C, Srivastava AK, Kapoor NK. Hypolipidemic activity of Achyranthus aspera Linn in normal and triton induced hyperlipemic rats. Indian J Exp Biol 1992;30:128-130.
25. Yamamoto K, Byrne R, Edelstein C, Shen B, Scanu AM. In vitro effect of Triton WR-1339 on canine plasma high density lipoproteins. J Lipid Res 1984;25:770-779.
26. Otway S, Robinson DS. The use of a non-ionic detergent (Triton WR 1339) to determine rates of triglyceride entry into the circulation of the rat under different physiological conditions. J Physiol (Lond) 1967;190:321-332.
27. Campillo JE, Torres MD, Dominguez E, Romero A, Ṕerez C. Ficus carica leaf administration reduces hypertrygliceridaemia in streptozotocin diabetic rats. Diabetologia 1994;37:A213.
28. Pérez C, Canal JR, Campillo JE, Romero A, Torres MD. Hypotriglyceridaemic activity of Ficus carica leaves in experimental hypertriglyceridaemic rats. Phytother Res 1999;13:188-191.
29. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998;98:2088-2093.
30. Al-Hiari Y, Shattat G, Al-Qirim T, El-Huneidi W, Abu Sheikha G,Hikmat S. Antihyperlipidemic properties of novel N-(benzoylphenyl)-5-substituted-1H- indole-2-carboxamides in triton WR-1339-induced hyperlipidemic rats. Molecules 2011;16: 8292-8304.